CTOs on the Move

Forma Therapeutics

www.formatherapeutics.com

 
At FORMA, patients are our purpose. We are dedicated to delivering transformative medicines to patients with cancer and rare diseases. We are a fully-integrated, privately-held clinical stage biopharmaceutical company. A leader in metabolism, epigenetics and protein homeostasis focused on the discovery, development and commercialization of transformative medicines. Our proprietary R&D platform combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. We have delivered high-value clinical candidates to our partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
John Bishop
 Chief Technology Officer Profile

Funding

Forma Therapeutics raised $100M on 12/19/2019

Similar Companies

Sunset Pharmaceuticals Inc

Sunset Pharmaceuticals Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardior Pharmaceuticals

Pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.

Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.

International Stem Cell Corporation

International Stem Cell Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.